Impact of Physical Activity and Weight Loss on Fat Mass, Glucose Metabolism, and Inflammation in Older African Americans with Osteoarthritis

Andrew McLeod 1,2,*, Linda Schiffer 2, Karla Castellanos 3, Andrew DeMott 2,4,*, Sarah Olender 3, Marian Fitzgibbon 2,5,6, Susan Hughes 2,4,7, Giamila Fantuzzi 1 and Lisa Tussing-Humphreys 1,2,6,*

1 Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL 60612, USA; amcleo2@uic.edu (A.M.); giamila@uic.edu (G.F.)
2 Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, USA; lschi@uic.edu (L.S.); ademot1@uic.edu (A.D.); mlf@uic.edu (M.F.); shughes@uic.edu (S.H.)
3 Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA; kcaste5@uic.edu (K.C.); solender10@gmail.com (S.O.)
4 Center for Research on Health and Aging, Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, USA
5 Department of Pediatrics, University of Illinois at Chicago, Chicago, IL 60612, USA
6 University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA
7 Department of Community Health Sciences, School of Public Health, University of Illinois at Chicago, Chicago, IL 60612, USA
* Correspondence: ltussing@uic.edu; Tel.: +1-312-355-5521

Received: 23 September 2020; Accepted: 27 October 2020; Published: 28 October 2020

Abstract: (1) Background: There are currently very few interventions performed within a community setting that compare the effects of physical activity (PA) versus PA plus weight loss on cancer and chronic disease risk in older African Americans. Therefore, we investigated the impact of an 8 week (24 session) PA intervention compared to a PA plus weight loss intervention on fat mass, glucose metabolism, and markers of inflammation in older, overweight and obese African Americans. (2) Methods: Subjects were randomized to a PA (n = 83) or PA plus weight loss (n = 72) intervention that met three times weekly for 8 weeks. At baseline and post-intervention, anthropometrics, body composition, systemic inflammation (high-sensitivity C-reactive protein, tumor necrosis factor-α, and interleukin 6), fasting glucose, insulin and homeostasis model assessment-insulin resistance (HOMA-IR) were determined. (3) Results: Subjects had a mean age of 67 years (SD = 5.3) and were mostly women (88%). The PA plus weight loss group lost more total and visceral fat than the PA group (−4.0% vs. +0.6% and −4.1% vs. +3.7%, respectively, p < 0.01 for both). Changes in inflammation and glucose metabolism were similar between groups post-intervention. Within the PA plus weight loss group only, serum insulin and HOMA-IR decreased significantly. (4) Conclusions: PA combined with weight loss can decrease total and visceral fat mass and improve insulin sensitivity, confirming that these cancer- and chronic disease-related risk factors are influenced by relatively modest lifestyle changes in the short term.

Keywords: cancer prevention; adiposity; insulin resistance; physical activity; dietary intervention; African American

1. Introduction

The United States population is at high risk for cancer and several chronic diseases, such as cardiovascular disease (CVD) and type 2 diabetes (T2D). Approximately 42% of the United States
Obesity and low levels of physical activity (PA) are risk factors for several types of cancer, including breast and colorectal cancers [4–9], and for several other non-communicable diseases, such as CVD [10,11], and T2D [12]. These risk factors are highly prevalent in African American (AA) women, with those 20 years and older having the highest rates of obesity and those aged 45–64 engaging in less PA than their non-Hispanic white counterparts [13,14]. The high prevalence of these risk factors may explain why, compared to non-Hispanic whites aged 55–79 years, AAs experience higher rates of esophageal, renal, colorectal, and advanced uterine cancers [15,16]. AAs, especially women, also have higher chronic disease risk such as for CVD [17] and T2D [18].

Obesity increases cancer, CVD, and T2D risk through several likely mechanisms, including a low-grade chronic pro-inflammatory response and glucose dysmetabolism [19–21]. Often accompanying obesity is an increased amount of circulating pro-inflammatory cytokines, such as interleukin-6 (IL-6), which can stimulate upregulation of anti-apoptotic genes [22,23]. Another of these pro-inflammatory cytokines is tumor necrosis factor-alpha (TNF-α), which enhances tissue proliferation and cancer metastasis [19,24]. The pro-inflammatory capacity of these cytokines also can lead to glucose dysmetabolism, characterized by hyperinsulinemia and hyperglycemia, both of which can promote carcinogenesis [19,25], CVD [20], and T2D [21].

Low levels of PA are associated with increased risk of cancer, CVD, and T2D through inflammation and glucose dysmetabolism as well [26–28]. Several cross-sectional studies show that, compared to adults who engage in higher levels of PA, those engaged in lower levels of PA have increased levels of the acute phase protein, C-reactive protein (CRP), and higher levels of IL-6, and TNF-α [29–34]. For example, Lamonte and colleagues showed that, among 4832 older, overweight, and ethnically diverse women, decreased PA measured objectively by accelerometry was associated with increased levels of CRP [32]. Given that inflammation is mechanistically linked to cancer and CVD, a decrease in PA may lead to increased cancer and CVD risk.

Numerous studies have also shown that decreased PA is associated with altered glucose metabolism. Lamonte and colleagues showed that decreased PA was associated with increased blood glucose and insulin levels [32]. In another study, McGlory and colleagues demonstrated that older, overweight adults who voluntarily decreased PA for one week developed insulin resistance that failed to resolve after two weeks of subsequent PA [35]. Given that glucose dysmetabolism is mechanistically linked to cancer and T2D, a decrease in PA may lead to increased cancer and T2D risk.

Obesity and low levels of PA may lead to cancer and chronic disease, suggesting that weight loss and an increase in PA may help prevent them. Studies show that, in older populations, weight loss and PA interventions result in reductions in CRP and pro-inflammatory biomarkers, such as TNF-α, IL-6, and IL-8 [36–41]. Furthermore, reductions in IL-6 and CRP have been significantly correlated with reduction in visceral adipose tissue (VAT) volume and total body fat mass [38]. Similar interventions have also led to reductions in blood glucose levels, improvements in insulin sensitivity, and decreased insulin levels in older populations [40,42,43]. Some interventions, however, have not resulted in decreased glucose levels [44,45]. This discrepancy may be due to the lower intensity of exercise in these studies compared to those in which glucose levels improved.

Despite the reported evidence that PA or PA plus weight loss can lower inflammation and improve glucose metabolism, only one randomized controlled trial has tested such interventions in predominately older AAs [46]. Many other trials have involved middle-aged adults and/or involved a majority of white participants [36–39,41,42,44,45,47–57]. Furthermore, to our knowledge, only two other studies have tested such interventions in a “real-world” setting—one in which the interventions are kept low cost and designed to be easily implemented into existing community structures, such as programming within local park districts [44,45]. Consequently, we tested the effect of PA alone (Fit and Strong! (F&S!)) or in combination with weight loss (Fit and Strong! Plus (F&S+ff)) among older, obese AAs on cancer, CVD, and T2D risk-related biomarkers, including markers of inflammation and glucose metabolism. We hypothesized that these biomarkers of cancer and chronic disease risk would
decrease significantly in both groups, but more so in participants randomized to F&S!+, owing to its greater emphasis on weight loss. Furthermore, given the strong connection between adipose tissue, inflammation and glucose dysmetabolism, we predicted that a reduction in total fat mass and VAT would correlate with a reduction in chronic disease-risk biomarkers, irrespective of overall weight loss.

2. Materials and Methods

2.1. Recruitment Strategy and Inclusion/Exclusion Criteria

This study is ancillary to a larger study that investigated the effectiveness of F&S!+, compared to F&S!, in reducing weight and improving diet quality, PA, osteoarthritis (OA) symptoms, anxiety, and depression among a cohort of 413 overweight and obese adults over the age of 60 years with self-reported lower-extremity (LE) OA residing primarily in Chicago, Illinois. (Grant # R01AG039374, NCT # 03180008) [58.] The interventions were conducted in Chicago Park District sites and local churches. Recruitment consisted of flyer distribution at local businesses, churches, and senior residences, and emails to subscribers of the Arthritis Foundation’s listserv. Interested persons were screened over the phone for both the parent and current study using the eligibility criteria below.

Inclusion criteria for the parent study stipulated that participants have LE OA determined by pain in or around at least one knee or hip most days in the past month, or pain or stiffness in or around hips, knees, ankles, feet, or lower back on most days of at least one month of the last six months; age 60 years and older; no current participation in a regular PA program and completing less than 150 min of combined moderate and vigorous PA per week; calculated body mass index (BMI) of 25–50 kg/m²; and ability to attend class at specified times and to participate in measurement and intervention procedures. Exclusion criteria included a score of three or more on the 10-item Mental Status Questionnaire [59]; uncomplicated hip or knee surgery within the previous six months or surgery with complications within the past year; steroid injections in either knee or hip within the previous three months; diagnosis of rheumatoid arthritis; uncontrolled diabetes, or health conditions that might interfere with exercise. The Exercise and Screening for You (EASY) screener [60] was used to identify health contraindications to exercise. Participants who reported one or more high-risk conditions on the EASY screener were required to obtain a physician’s approval before participating.

The ancillary study (American Cancer Society of Illinois, #261775) had the same inclusion criteria. In addition, participants had to self-report a body weight of 450 pounds or less, be cancer free for the previous five years, and self-describe as AA. Exclusion criteria were the same. A subsample of participants (n = 155) from the parent study participated in the ancillary study procedures (i.e., blood draw, and body composition via dual energy X-ray absorptiometry (DXA)).

The University of Illinois at Chicago (UIC) Institutional Review Board reviewed and approved both the parent and ancillary study (2012-0277; 2013-0098). Prior to enrolling in the parent and ancillary study, participants provided informed, written consent.

2.2. Parent Study Interventions

A full description of the parent study design and methods is reported elsewhere [58]. Briefly, F&S! is an evidence-based PA program which the Centers for Disease Control and Prevention and National Council on Aging recommend for older adults with OA [61]. The program seeks to reduce the number and severity of OA-related symptoms through strengthening of muscle and bone. It also aims to promote behavior change by reinforcing self-efficacy for exercise and exercise adherence. Certified fitness instructors carry out these aims in thrice weekly 90 min sessions for eight consecutive weeks. Eight weeks was chosen to keep costs lower compared to most other interventions which last at least 16 weeks. This makes the intervention easy to disseminate, both by simplifying training of staff and by avoiding participant burnout. At each session, a certified fitness instructor focused on flexibility/balance, aerobics, and lower-extremity strengthening exercises for twenty minutes each.
For thirty minutes afterward, the instructor facilitated a group discussion on, and used a structured curriculum to provide education about, OA symptom management.

F&S!+ is the same as F&S! in many components but not all. The instructor-led sessions of F&S! related to OA symptom management are condensed to facilitate the addition of sixteen sessions focusing on calorie reduction and improving diet quality to help participants lose weight. Emphasis is also placed on weight loss self-efficacy through the use of food diaries and weekly weigh ins, which help participants track positive changes. Ultimately, F&S!+ aims to promote PA, healthy eating behaviors, self-efficacy associated with both, and 5% weight loss within 6 months.

2.3. Study Measures and Data Collections Methods

Data were collected from participants at the beginning of the intervention and at eight weeks. At baseline and follow up, ancillary study participants completed surveys and physical assessments and underwent a whole-body DXA scan and a fasting venous blood draw. Participants also refrained from vigorous exercise for 24 h and refrained from non-steroidal anti-inflammatory drugs, insulin, oral hypoglycemic agents, and dietary supplements. They wore metal-free clothing (for DXA scan) and had to be cold and flu free for at least seven days preceding data collection.

Demographic information was collected at baseline with a standard interviewer-administered questionnaire. A health history questionnaire was given to record self-reported disease status and medication usage. Trained research staff measured height in duplicate at baseline to the nearest 0.1 cm with a stadiometer and measured weight in duplicate at both visits to the nearest 0.1 kg with a digital scale. Waist circumference was measured just above the iliac crest at the mid-axillary line to the nearest 0.1 cm, using a Gulick 150 cm anthropometric tape. Body composition, including total fat mass, estimated VAT and lean mass, was measured via DXA. If a participant was too large to have a whole-body DXA scan, a half scan was completed and whole-body composition was calculated from the half scan.

Fasting venous blood samples were processed for serum, aliquoted, and stored at −80 °C until analysis. Systemic inflammation was measured through CRP, IL-6, and TNF-α. High-sensitivity CRP was analyzed at Quest Diagnostics (Wood Dale, IL, USA) via nephelometry. IL-6 was analyzed at UIC with Quantikine® HS Human Immunoassay for IL-6 (R&D Systems, Minneapolis, MN, USA). TNF-α was analyzed via ELISA using the Quantikine Human TNF-α Immunoassay (R&D Systems, Minneapolis, MN, USA). Glucose metabolism was measured through fasting serum glucose and fasting serum insulin. Fasting serum glucose was measured via spectrophotometry and fasting serum insulin via immunoassay at Quest Diagnostics (Wood Dale, IL, USA). Insulin resistance was calculated from the homeostatic assessment—insulin resistance (HOMA-IR) model equation [HOMA-IR = fasting insulin (mU/L) × fasting glucose (mmol/L)/22.5] [63].

2.4. Power and Statistical Analysis

For this ancillary study, we performed an a priori power analysis using PASS software (2008, Kaysville, UT, USA) from published data. Group sample sizes of 71 in customary F&S! and 71 in F&S!+ could provide 80% power to detect moderate effect sizes (0.47–0.48) for the pro-inflammatory cytokines (CRP, IL-6, and TNF-α). With an estimated 5% attrition rate from formative work, 150 subjects were recruited (75/group) to achieve adequate power to detect the effect sizes [36,41].

Data were collected via paper-based questionnaire and entered into a Research Electronic Capture (REDCap) database. Prior to statistical analysis, data entry errors and the distribution of variables were assessed. Because of their non-normal distribution, CRP, IL-6, TNF-α, glucose, insulin and HOMA-IR were log transformed for analysis. Because we used a subset of a larger randomized sample, differences by treatment group at baseline were assessed via t-test, chi-square test or a non-parametric equivalent. Between- and within-group changes from baseline to post-intervention, adjusted for baseline BMI, gender, age, and intervention site/iteration, were assessed using generalized estimating equations (GEE), a method that accounts for intra-individual correlation over time [64]. The weight
and BMI models did not include baseline BMI as a covariate, since the baseline value was included in the outcome vector. Adjusted baseline and post-intervention mean and geometric mean were also estimated from these models. Spearman rank correlations were used to examine relationships between changes in biomarkers (insulin, glucose, TNF-α, IL-6, and CRP) and changes in VAT mass and total fat mass, adjusted for change in body weight for the total sample combined. The statistical significance of these correlations was assessed with and without correction for multiple testing ($p < 0.005$ or $p < 0.05$). For other analyses, $p$-values of $<0.05$ were considered statistically significant. All analyses were conducted with SAS software (version 9.4, SAS Institute, Cary, NC, USA).

### 3. Results

Table 1 shows demographic and health characteristics of participants included in the ancillary study ($n = 155$). The majority were 60 to 69 years of age, female, retired, and had at least some college experience. There were no differences at baseline between groups for any of the demographic variables.

Table 1. Demographic and health characteristics of participants.

|                      | Fit and Strong! ($n = 72$) | Fit and Strong! ($n = 83$) | All ($n = 155$) |
|----------------------|-----------------------------|-----------------------------|-----------------|
| **Age, year, mean (SD)** | 66.5 (4.8) | 67.2 (5.7) | 66.9 (5.3) |
| **Aged 60–69 years, n (%)** | 60 (83%) | 61 (73%) | 121 (78%) |
| **Aged ≥70 years, n (%)** | 12 (17%) | 22 (27%) | 34 (22%) |
| **Female, n (%)** | 64 (89%) | 73 (88%) | 137 (88%) |
| **Education, year, mean (SD)** | 14.3 (1.6) | 13.9 (2.1) | 14.1 (1.9) |
| **Not HS graduate, n (%)** | 3 (4%) | 9 (11%) | 12 (8%) |
| **HS graduate/GED, n (%)** | 10 (14%) | 9 (11%) | 19 (12%) |
| **Some college or tech school, n (%)** | 32 (44%) | 38 (46%) | 70 (45%) |
| **College graduate, n (%)** | 27 (38%) | 27 (33%) | 54 (35%) |
| **Retired, n (%)** | 49 (68%) | 63 (76%) | 112 (72%) |
| **Married, n (%)** | 12 (17%) | 17 (20%) | 29 (19%) |
| **Income, median** | 25,000 | 25,000 | 25,000 |
| **Chronic conditions**, mean (SD) | 2.7 (1.5) | 3.1 (1.9) | 2.9 (1.7) |
| **Type 2 diabetes, n (%)** | 19 (26%) | 25 (30%) | 44 (28%) |
| **Hypertension, n (%)** | 58 (81%) | 66 (80%) | 124 (80%) |
| **Heart disease, n (%)** | 8 (11%) | 11 (13%) | 19 (12%) |

1 $n = 132$ for income. 2 Number of self-reported conditions (of 17) currently affecting health.

Table 2 shows anthropometric and body composition means at baseline and post-intervention adjusted for gender, age, iteration, and baseline BMI. Importantly, at baseline, there were no statistically significant differences between groups for any of the variables in Table 2. There were several significant within- and between-group differences at post-intervention. Weight, BMI, waist circumference, and % body fat decreased significantly more in F&S!+ compared to F&S!. Total fat mass decreased significantly within F&S!+ ($−4.0\%$, $p < 0.001$) compared to F&S! ($+0.6\%$, $p > 0.05$) and the difference was statistically significant ($p < 0.001$). The same pattern occurred with VAT mass ($−4.1\%$ vs. $+3.7\%$, $p < 0.05$) and VAT volume ($−4.1\%$ vs. $+3.7\%$, $p < 0.05$). Percent lean mass increased significantly in F&S!+ but not in F&S!, and the between-group difference was significant ($1.5\%$ vs. $0.2\%$, respectively; $p < 0.001$). However, absolute lean mass did not change over time in either group. Attendance was similar between groups, with F&S! attending on average 70% of classes and F&S!+ attending 64% of classes.
Table 2. Anthropometrics and body composition: adjusted \(^1\) means at baseline and post-intervention visits.

|                          | Fit and Strong\(^+\) |                                      | Fit and Strong\(^+\) |
|--------------------------|----------------------|--------------------------------------|----------------------|
|                          | Baseline (n = 72)    | Post-Int (n = 69)                    | Baseline (n = 83)    | Post-Int (n = 74) |
|                          | Mean (SE)            | Mean (SE)                            | Mean (SE)            | Mean (SE)         |
|                          |                      |                                      |                      |                    |
| Weight, kg               | 95.5 (2.7)           | 93.6 (2.7)                           | 97.2 (2.3)           | 97.0 (2.3)        |
| BMI, kg/m\(^2\)          | 33.7 (0.9)           | 33.0 (0.9)                           | 33.9 (0.8)           | 33.8 (0.8)        |
| Waist, cm                | 115.3 (1.0)          | 113.1 (1.0)                          | 114.7 (1.0)          | 114.8 (1.0)       |
| % body fat               | 41.6 (0.4)           | 40.7 (0.4)                           | 41.3 (0.4)           | 41.2 (0.4)        |
| Fat mass, g              | 41348 (663)          | 39699 (705)                          | 41325 (599)          | 41282 (631)       |
| % lean mass              | 55.4 (0.4)           | 56.2 (0.4)                           | 55.7 (0.4)           | 55.8 (0.4)        |
| Lean mass, g             | 53603 (783)          | 53394 (783)                          | 54577 (629)          | 54561 (629)       |
| VAT mass, g              | 1992 (102)           | 1910 (118)                           | 1987 (85)            | 2062 (85)         |
| Baseline VAT volume, cm  | 2112 (109)           | 2024 (125)                           | 2107 (90)            | 2185 (91)         |
| % body fat               | 0.7 (2.1%)           | 0.8 (1.5%)                           | 0.8 (1.5%)           | 0.4 (0.2%)        |
| CRP, mg/L                | 4.5 (3.1–6.4)        | 4.2 (3.0–6.0)                        | 3.5 (2.5–4.8)        | 3.4 (2.5–4.7)     |
| IL-6, pg/mL              | 3.6 (3.1–4.3)        | 3.8 (3.2–4.4)                        | 3.2 (2.7–3.7)        | 3.2 (2.8–3.8)     |
| TNF-α, pg/mL             | 6.9 (4.3–10.9)       | 4.9 (3.0–8.1)                        | 5.8 (3.6–9.4)        | 3.7 (2.2–6.2)     |
| Glucose, mg/dL           | 104.0 (98.1–102.2)   | 99.9 (94.2–106.1)                    | 102.9 (98.0–108.0)   | 104.4 (98.5–110.6)|
| Insulin, mU/mL           | 11.1 (9.3–13.6)      | 9.6 (7.7–12.0)                       | 9.8 (7.9–12.2)       | 9.4 (7.7–11.6)    |
| HOMA-IR                  | 2.9 (2.3–3.8)        | 2.4 (1.8–3.0)                        | 2.5 (2.0–3.2)        | 2.4 (1.9–3.1)     |

\(^1\) From GEE models adjusted for gender, age, site, and baseline BMI. E(Y) = α + β1group + β2time + β3group × time + β4gender + β5age + β6site + β7 (baseline BMI). All biomarker variables are log-transformed to improve normality. Ns differ slightly for some biomarker variables. 2 Test for within-group difference in change from baseline to post-intervention visit: * p < 0.05, ** p < 0.01, and *** p < 0.001. 3 Test for difference between groups in change from baseline to post-intervention visit. BMI = body mass index; VAT = visceral adipose tissue.

Table 3 shows no statistically significant differences at baseline between groups for any variable listed. Fasting serum insulin and HOMA-IR decreased significantly in F&S! (+13.9% and −17.3%, respectively; p < 0.05 for both) but not in F&S!; however, there was no significant between-group difference.

Table 3. Cancer-risk biomarker variables: adjusted \(^1\) geometric means at baseline and post-intervention visits.

|                          | Fit and Strong\(^+\) |                                      | Fit and Strong\(^+\) |
|--------------------------|----------------------|--------------------------------------|----------------------|
|                          | Baseline (n = 72)    | Post-Int (n = 69)                    | Baseline (n = 83)    | Post-Int (n = 74) |
|                          | Mean (95% CI)        | Mean (95% CI)                        | Mean (95% CI)        | Mean (95% CI)     |
|                          |                      |                                      |                      |                    |
| CRP, mg/L                | 4.5 (3.1–6.4)        | 4.2 (3.0–6.0)                        | 3.5 (2.5–4.8)        | 3.4 (2.5–4.7)     |
| IL-6, pg/mL              | 3.6 (3.1–4.3)        | 3.8 (3.2–4.4)                        | 3.2 (2.7–3.7)        | 3.2 (2.8–3.8)     |
| TNF-α, pg/mL             | 6.9 (4.3–10.9)       | 4.9 (3.0–8.1)                        | 5.8 (3.6–9.4)        | 3.7 (2.2–6.2)     |
| Glucose, mg/dL           | 104.0 (98.1–102.2)   | 99.9 (94.2–106.1)                    | 102.9 (98.0–108.0)   | 104.4 (98.5–110.6)|
| Insulin, mU/mL           | 11.1 (9.3–13.6)      | 9.6 (7.7–12.0)                       | 9.8 (7.9–12.2)       | 9.4 (7.7–11.6)    |
| HOMA-IR                  | 2.9 (2.3–3.8)        | 2.4 (1.8–3.0)                        | 2.5 (2.0–3.2)        | 2.4 (1.9–3.1)     |

\(^1\) From GEE models adjusted for gender, age, site, and baseline BMI. E(Y) = α + β1group + β2time + β3group × time + β4gender + β5age + β6site + β7 (baseline BMI). All biomarker variables are log-transformed to improve normality. Ns differ slightly for some biomarker variables. 2 Test for within-group difference in change from baseline to post-intervention visit: * p < 0.05. 3 Test for difference between groups in change from baseline to post-intervention visit. CRP = C-reactive protein; IL = interleukin; TNF-α = tumor necrosis factor-alpha; HOMA-IR = homeostasis model assessment-insulin resistance.

Table 4 shows that the change in CRP post-intervention was significantly positively correlated with change in VAT mass, independent of change in weight (r = 0.33, p = 0.0006). Change in total fat mass was significantly positively correlated with change in fasting glucose, independent of change in weight (r = 0.29, p = 0.003). Likewise, change in total fat mass was also correlated with change in CRP but, after Bonferroni correction for multiple testing, the correlation was no longer significant (r = 0.27, p = 0.050).
was not superior in regard to improving inflammation or glucose metabolism-related biomarkers. The relatively small sample size in our study may have also precluded our ability to observe significant between-group differences for changes in cancer-risk biomarkers with changes in VAT mass and total fat mass, adjusted for change in weight.

### Table 4. Partial Spearman rank correlations for changes in cancer-risk biomarkers with changes in VAT mass and total fat mass, adjusted for change in weight.

|                  | Δ Insulin, μIU/mL | Δ Glucose, mg/dL | Δ TNF-α, pg/mL | Δ IL-6, μIU/mL | Δ CRP, mg/L |
|------------------|-------------------|------------------|----------------|----------------|-------------|
| Δ VAT mass, g     | \( r = 0.018 \)   | \( r = 0.11 \)   | \( r = 0.12 \) | \( r = 0.14 \) | \( r = 0.33 \) |
|                  | \( p = 0.86 \)    | \( p = 0.27 \)   | \( p = 0.24 \) | \( p = 0.16 \) | \( p = 0.0006 \) |
| Δ Total fat mass, g | \( r = 0.053 \)   | \( r = 0.29 \)   | \( r = 0.11 \) | \( r = 0.16 \) | \( r = 0.27 \) |
|                  | \( p = 0.59 \)    | \( p = 0.0027 \) | \( p = 0.26 \) | \( p = 0.096 \) | \( p = 0.005 \) |

\(^1\) Significant at \( p < 0.005 \) (Bonferroni correction for multiple testing: 0.05/10). VAT = visceral adipose tissue, TNF = tumor necrosis factor, IL = interleukin, CRP = C-reactive protein.

4. Discussion

Our results show that an 8 week (24 session) PA plus weight loss intervention (F&S+) in older, overweight and obese AAs with osteoarthritis can produce decreases in body fat and VAT that are significantly greater than the changes produced by the PA intervention (F&S!) alone. This finding is consistent with previous studies comparing the effects of PA versus PA plus weight loss on body fat and body fat distribution in older adults [37,38,47–49]. However, unlike previous studies, our findings are from a primarily African American cohort. Contrary to our hypothesis, the F&S+ intervention was not superior in regard to improving inflammation or glucose metabolism-related biomarkers compared to F&S!. Nonetheless, within groups, we saw a significant reduction in fasting serum insulin and HOMA-IR in F&S+, and a significant reduction in TNF-α in the F&S! group post-intervention.

Studies examining the effect of PA and PA plus weight loss on inflammation and glucose metabolism-related biomarkers in older, overweight and obese adults is somewhat mixed. We surmise that the lack of effect in our study may be a result of the short intervention period and relatively low-intensity PA overall and modest decreases in total fat mass (4.0%) and VAT mass (4.1%) in the F&S+ group. Total fat mass and VAT mass have been shown to be related to IL-6, CRP, and TNF-α [19,23,24] and glucose metabolism-related biomarkers [65]. In other studies measuring and reporting total fat mass and VAT mass, the PA plus weight loss groups achieved at least a 10% decrease in total fat mass [42,47,49] and/or VAT fat mass [37,38,42]. The greater decreases in total fat and VAT mass in these studies are likely due in part to the longer duration of the interventions, with most lasting at least 1 year. Thus, in our study, a longer intervention may have led to greater between-group differences for total fat and VAT mass that would have translated to significant improvement in pro-inflammatory and glucose metabolism-related biomarkers. The relatively small sample size in our study may have also precluded our ability to observe significant between-group effects given studies reporting significant results had at least 100 subjects per treatment arm [36,38].

Our within-group effects on glucose metabolism and pro-inflammatory-related biomarkers were encouraging. For example, fasting serum insulin and HOMA-IR decreased significantly from baseline in the F&S+ group. The decrease in HOMA-IR is important given the cut-off value for defining insulin resistance using HOMA-IR is 2.6 and the F&S+ group fell below this cut off, suggesting that the intervention was successful in ameliorating insulin resistance [66]. Surprisingly, TNF-α decreased significantly in F&S! but not the F&S+ group although the magnitude of decrease was similar in both groups. This result may merely be an experimental artefact and not indicative of a true, underlying biological mechanism given F&S+ had the same amount of PA and, over time, saw significant decreases in overall and VAT fat mass. Moreover, attendance at group sessions and physical activity participation was similar between the groups meaning differential adherence to the intervention protocol does not explain the difference [67]. The effects of PA and PA plus weight loss on TNF-α in older adults have varied. Tomeleri and colleagues reported that 8 weeks of resistance exercise training in obese, older women was associated with significantly lower TNF-α post-intervention compared to controls [50]. However, Nicklas and colleagues reported no statistically significant decrease in TNF-α in older, overweight and obese women following an 18 month PA plus weight loss intervention [41]. Nicklas suggested that lack of decrease in TNF-α may be due to the protein’s transient production.
and short half-life. Moreover, Friedenreich and colleagues reported no change in TNF-α following a 12 month aerobic exercise intervention among post-menopausal women [39]. Both Nicklas and Friedenreich suggested that TNF-soluble receptors may glean more robust results of the effects of PA and PA plus weight loss on the biological activity of TNF-α given it is a more stable protein [68].

In previous studies, VAT mass was found to be positively associated with pro-inflammatory cytokines such as IL-6 [23,38] and the acute phase protein, CRP [38,39], and increased overall adiposity is positively associated with TNF-α [19,24] and CRP [38,39]. Somewhat consistent with previous literature, our study showed that decreased VAT mass and total fat mass were positively correlated with decreases in CRP. Moreover, not only was there a correlation between decreased CRP and both VAT mass and total fat mass, the correlation existed independently of weight loss. These findings suggest that even if overall weight remains stable during an intervention, but VAT mass and total fat mass is reduced, it can translate to a concurrent reduction in CRP. However, in contrast to CRP, decreased total fat mass and VAT mass was not correlated with changes in IL-6 or TNF-α. It is possible that the null result for IL-6 is related to the only modest changes to the measures of adiposity given up to 25% of IL-6 originates from adipose tissue [69]. The null result for TNF-α may have been due to the transient production and short half-life of circulating TNF-α [41]. However, it is also possible that the interventions caused a local vs. paracrine effect on TNF-α activity given studies suggesting that local adipose expression of TNF-α versus circulating concentrations are affected more with increased adiposity [70]. Nonetheless, Beavers and colleagues, did detect a significant positive correlation between changes in VAT mass and circulating IL-6 in response to weight loss in older overweight and obese adults with OA. The method used to assess VAT was computed tomography (CT), a more accurate tool to measure VAT than DXA. This likely allowed for detection of even subtle changes in VAT mass [38].

This study had several strengths. It recruited a cohort that is underrepresented in the literature and collected a wealth of information, including cancer- and chronic disease-risk biomarkers and detailed body composition measurements. It also examined the effect of an intervention conducted in a community setting, that is, a setting wherein environmental variables, more so than artificial experimental variables, shape participant behavior and health. Furthermore, the interventions are kept low cost and designed to be easily implemented into existing community structures, such as programming within local park districts. This allows for maximal generalizability.

This study did have limitations, however. First, the intervention lasted only 8 weeks, and one-third of the PA sessions consisted of flexibility and balance training, two activities requiring very limited energy expenditure. This means the interventions may not have been long enough or energy-intensive enough to see clinically significant weight loss (3–5%). Additionally, the nutrition aspect of F&S+ was not implemented by a trained nutritionist or dietitian. This feature may have rendered the intervention less effective, but also increases the likelihood that the intervention can be replicated successfully in the community. Further, though the interventionists were not necessarily credentialed, they were trained for 14 h. Second, insulin resistance was calculated using the HOMA-IR equation. It was not measured with the hyperinsulinemic-euglycemic clamp, which is the gold standard [71]. This limitation is understandable given the considerable resources needed to perform this procedure (e.g., tightly controlled diet and activity in an in-patient setting) [42]. Third, given the comparative effectiveness design, there was no true control group, which would have allowed for a test of the independent effects of PA. Fourth, the sample size was a limitation. Between-group differences in glucose and HOMA-IR were nearly significant and might have reached significance with greater numbers of participants. Furthermore, other studies with similar sample sizes also did not show differences between the PA and PA plus weight loss groups for inflammatory markers [41,72]. Lastly, all of our subjects had self-reported LE OA. Systemic inflammation is higher in this population [41]. Thus, it is possible that our findings are limited to overweight and obese older adults with this condition.
5. Conclusions

In conclusion, while PA plus weight loss (F&S!+) did not significantly decrease pro-inflammatory or glucose metabolism-related biomarkers more than PA alone (F&S!) did, it did decrease overall and visceral fat mass, both of which are associated with increased cancer and chronic disease risk. Furthermore, within F&S!+ but not F&S!, fasting serum insulin and HOMA-IR decreased significantly. Due to the relatively uncontrolled conditions in this study and its short duration, the improvements in cancer- and chronic disease-risk biomarkers, though small, suggest that longer trials might have greater benefit for preventing cancer and chronic disease.

Author Contributions: Conceptualization, L.T.-H. and A.M.; methodology, M.F., S.H. and L.T.-H.; laboratory analysis, G.F. and K.C.; statistical analysis, L.S., A.M., and L.T.-H.; data curation, A.D. and S.O.; writing—original draft preparation, L.T.-H. and A.M.; writing—review and editing, all authors; funding acquisition, S.H., M.F. and L.T.-H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Institutes of Health, grant number R01AG039374 awarded to S.H. and M.F.; and the American Cancer Society of Illinois, grant number #261775 awarded to L.T.-H.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef] [PubMed]
2. Wilkins, J.T.; Ning, H.; Berry, J.; Zhao, L.; Dyer, A.R.; Lloyd-Jones, D.M. Lifetime Risk and Years Lived Free of Total Cardiovascular Disease. JAMA 2012, 308, 1795–1801. [CrossRef] [PubMed]
3. Narayan, K.M.V.; Boyle, J.P.; Thompson, T.J.; Sorensen, S.W.; Williamson, D.F. Lifetime Risk for Diabetes Mellitus in the United States. JAMA 2003, 290, 1884–1890. [CrossRef] [PubMed]
4. Liu, Y.; Hu, F.; Li, D.; Wang, F.; Zhu, L.; Chen, W.; Ge, J.; An, R.; Zhao, Y. Does Physical Activity Reduce the Risk of Prostate Cancer? A Systematic Review and Meta-Analysis. Eur. Urol. 2011, 60, 1029–1044. [CrossRef] [PubMed]
5. Lee, I.; Oguma, Y. Physical Activity. In Cancer Epidemiology and Prevention; Schottenfeld, D., Fraumeni, J., Eds.; Oxford University Press: New York, NY, USA, 2009; pp. 1–92.
6. Frank, L.L.; Sorensen, B.E.; Yasui, Y.; Tworoger, S.S.; Schwartz, R.S.; Ulrich, C.M.; Irwin, M.L.; Rudolph, R.E.; Rajan, K.B.; Stanczyk, F.; et al. Effects of Exercise on Metabolic Risk Variables in Overweight Postmenopausal Women: A Randomized Clinical Trial. Obes. Res. 2005, 13, 615–625. [CrossRef] [PubMed]
7. McEltman, A. Cancer Prevention and Management through Exercise and Weight Control, 1st ed.; Taylor & Francis: Boca Raton, FL, USA, 2006.
8. De Pergola, G.; Silvestris, F. Obesity as a Major Risk Factor for Cancer. J. Obes. 2013, 2013, 291546. [CrossRef] [PubMed]
9. Oyeyemi, S.O.; Braaten, T.; Licaj, I.; Lund, E.; Benjaminsen Borch, K. Physical Activity Patterns and the Risk of Colorectal Cancer in the Norwegian Women and Cancer Study: A Population-Based Prospective Study. BMC Cancer 2018, 18, 1216. [CrossRef] [PubMed]
10. The Emerging Risk Factors Collaboration. Separate and Combined Associations of Body-Mass Index and Abdominal Adiposity with Cardiovascular Disease: Collaborative Analysis of 58 Prospective Studies. Lancet 2011, 377, 1085–1095. [CrossRef]
11. Stamatakis, E.; Hamer, M.; Dunstain, D.W. Screen-Based Entertainment Time, All-Cause Mortality, and Cardiovascular Events: Population-Based Study with Ongoing Mortality and Hospital Events Follow-Up. J. Am. Coll. Cardiol. 2011, 57, 292–299. [CrossRef]
12. Chatterjee, S.; Khunti, K.; Davies, M.J. Type 2 Diabetes. Lancet 2017, 389, 2239–2251. [CrossRef]
13. August, K.J.; Sorkin, D.H. Racial/Ethnic Disparities in Exercise and Dietary Behaviors of Middle-Aged and Older Adults. J. Gen. Intern. Med. 2011, 26, 245–250. [CrossRef] [PubMed]
14. Hales, C.M.; Carroll, M.D.; Fryar, C.D.; Ogden, C.L. Prevalence of Obesity Among Adults and Youth: United States, 2015–2016; NCHS Data Brief, no 288; NCHS: Hyattsville, MD, USA, 2017.
15. SEER. Available online: http://seer.cancer.gov/canques/incidence.html (accessed on 10 September 2016).
16. Henley, S.J.; Miller, J.W.; Dowling, N.F.; Benard, V.B.; Richardson, L.C. Uterine Cancer Incidence and Mortality—United States, 1999–2016. *Morb. Mortal. Wkly. Rep.* 2018, 67, 1333–1338. [CrossRef] [PubMed]
17. Davis, A.M.; Vinci, L.M.; Okwuoza, T.M.; Chase, A.R.; Huang, E.S. Cardiovascular Health Disparities: A Systematic Review of Health Care Interventions. *Med. Care Res. Rev.* 2007, 64, 295–1005. [CrossRef] [PubMed]
18. National Diabetes Fact Sheet, 2011. Available online: https://www.cdc.gov/diabetes/pubs/pdf/methods11.pdf (accessed on 10 September 2016).
19. Font-burgada, J.; Sun, B.; Karin, M. Review Obesity and Cancer: The Oil That Feeds the Flame. *Cell Metab.* 2015, 23, 48–62. [CrossRef] [PubMed]
20. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms Linking Obesity with Cardiovascular Disease. *Nature* 2006, 444, 875–880. [CrossRef]
21. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes. *Nature* 2006, 444, 840–846. [CrossRef] [PubMed]
22. Yu, H.; Pardoll, D.; Jove, R.; Comprehensive, K. HHS Public Access. *Nat. Rev. Cancer* 2016, 9, 798–809. [CrossRef]
23. Fontana, L.; Eagon, J.C.; Trujillo, M.E.; Scherer, P.E.; Klein, S. Systemic Inflammation in Obese Humans. *Diabetes* 2007, 56, 1010–1013. [CrossRef] [PubMed]
24. Greenberg, A.S.; Obin, M.S. Obesity and the Role of Adipose Tissue in Inflammation and Metabolism. *Am. J. Clin. Nutr.* 2006, 83, 461–465. [CrossRef] [PubMed]
25. Hanahan, D.; Weinberg, R.A. Review Hallmarks of Cancer: The Next Generation. *Cell* 2011, 144, 646–674. [CrossRef] [PubMed]
26. Roberts, D.L.; Dive, C.; Renehan, A.G. Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives. *Annu. Rev. Med.* 2010, 61, 301–316. [CrossRef] [PubMed]
27. Tian, D.; Meng, J. Exercise for Prevention and Relief of Cardiovascular Disease: Prognoses, Mechanisms, and Approaches. *Oxid. Med. Cell. Longev.* 2019, 2019, 3756750. [CrossRef] [PubMed]
28. Stanford, K.I.; Goodyear, L.J. Exercise and Type 2 Diabetes: Molecular Mechanisms Regulating Glucose Uptake in Skeletal Muscle. *Adv. Physiol. Educ.* 2014, 38, 308–314. [CrossRef]
29. Campbell, K.L.; McTiernan, A. Exercise and Biomarkers for Cancer Prevention Studies. *J. Nutr.* 2007, 137, 1615–1695. [CrossRef] [PubMed]
30. Tsukui, S.; Kanda, T.; Nara, M.; Nishino, M.; Kondo, T.; Kobayashi, I. Moderate-Intensity Regular Exercise Decreases Serum Tumor Necrosis Factor-α and HbA1c Levels in Healthy Women. *Int. J. Obes.* 2000, 24, 1207–1211. [CrossRef] [PubMed]
31. Ford, E.S. Does Exercise Reduce Inflammation? Physical Activity and C-Reactive Protein Among U.S. Adults. *Epidemiology* 2002, 13, 561–568. [CrossRef] [PubMed]
32. LaMonte, M.J.; Lewis, C.E.; Buchner, D.M.; Evenson, K.R.; Rillamas-Sun, E.; Di, C.; Lee, I.M.; Bellettiere, J.; Stefanick, M.L.; Eaton, C.B.; et al. Both Light Intensity and Moderate-to-Vigorous Physical Activity Measured by Accelerometry Are Favorably Associated with Cardiometabolic Risk Factors in Older Women: The Objective Physical Activity and Cardiovascular Health (Opach) Study. *J. Am. Heart Assoc.* 2017, 6, 1–15. [CrossRef] [PubMed]
33. Geffken, D.F.; Cushman, M.; Burke, G.L.; Polak, J.F.; Sakkinen, P.A.; Tracy, R.P. Association between Physical Activity and Markers of Inflammation in a Healthy Elderly Population. *Am. J. Epidemiol.* 2001, 153, 242–250. [CrossRef] [PubMed]
34. Vella, C.A.; Allison, M.A.; Cushman, M.; Jenny, N.S.; Miles, M.P.; Larsen, B.; Lakoski, S.G.; Michos, E.D.; Blaha, M.J. Physical Activity and Adiposity-Related Inflammation: The MESA. *Med. Sci. Sports Exerc.* 2017, 49, 915–921. [CrossRef] [PubMed]
35. McClory, C.; Von Allmen, M.T.; Stokes, T.; Morton, R.W.; Hector, A.J.; Lago, B.A.; Raphenya, A.R.; Smith, B.K.; McArthur, A.G.; Steinberg, G.R.; et al. Failed Recovery of Glycemic Control and Myofibrillar Protein Synthesis with 2 wk of Physical Inactivity in Overweight, Prediabetic Older Adults. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2018, 73, 1070–1077. [CrossRef] [PubMed]
36. Imayama, I.; Ulrich, C.M.; Alfano, C.M.; Wang, C.; Xiao, L.; Wener, M.H.; Campbell, K.L.; Duggan, C.; Foster-Schubert, K.E.; Kong, A.; et al. Effects of a Caloric Restriction Weight Loss Diet and Exercise on Inflammatory Biomarkers in Overweight/Obese Postmenopausal Women: A Randomized Controlled Trial. *Cancer Res.* 2012, 72, 2314–2326. [CrossRef] [PubMed]
37. Bouchonville, M.; Armamento-Villareal, R.; Shah, K.; Napoli, N.; Sinacore, D.R.; Qualls, C.; Villareal, D.T. Weight Loss, Exercise or Both and Cardiometabolic Risk Factors in Obese Older Adults: Results of a Randomized Controlled Trial. *Int. J. Obes.* 2014, 38, 423–431. [CrossRef] [PubMed]

38. Beavers, K.M.; Beavers, D.P.; Newman, J.J.; Anderson, A.M.; Loesser, R.F.; Nicklas, B.J.; Lyles, M.E.; Miller, G.D.; Mihalko, S.L.; Messier, S.P. Effects of Total and Regional Fat Loss on Plasma CRP and IL-6 in Overweight and Obese, Older Adults with Knee Osteoarthritis. *Osteoarthr. Cartil.* 2015, 23, 249–256. [CrossRef] [PubMed]

39. Friedenreich, C.M.; Neilson, H.K.; Woolcott, C.G.; Wang, Q.; Stanczyk, F.Z.; McTiernan, A.; Jones, C.A.; Irwin, M.L.; Yasui, Y.; Courneya, K.S. Inflammatory Marker Changes in a Yearlong Randomized Exercise Intervention Trial among Postmenopausal Women. *Cancer Prev. Res.* 2012, 5, 98–108. [CrossRef]

40. Mendoza-Nuñez, V.M.; Arista-Ugalde, T.L.; Rosado-Pérez, J.; Ruiz-Ramos, M.; Santiago-Osorio, E. Hypoglycemic and Antioxidant Effect of Tai Chi Exercise Training in Older Adults with Metabolic Syndrome. *Clin. Interv. Aging* 2018, 13, 523–531. [CrossRef]

41. Nicklas, B.J.; Ambrosius, W.; Messier, S.P.; Miller, G.D.; Penninx, B.W.J.H.; Loesser, R.F.; Palla, S.; Bleecker, E.; Pahor, M. Diet-Induced Weight Loss, Exercise, and Chronic Inflammation in Older, Obese Adults: A Randomized Controlled Clinical Trial. *Am. J. Clin. Nutr.* 2004, 79, 544–551. [CrossRef]

42. Yassine, H.N.; Marchetti, C.; Lim, M.; Stanczyk, F.Z.; McTiernan, A.; Kirwan, J.P. Effects of Exercise and Caloric Restriction on Insulin Resistance and Cardiometabolic Risk Factors in Older Obese Adults—A Randomized Controlled Clinical Trial. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2009, 64, 90–95. [CrossRef]

43. Malin, S.; Niemi, N.; Solomon, T.; Haus, J.; R Kelly, K.; Filion, J.; Rocco, M.; Kashyap, S.; Barkoukis, H.; Kirwan, J. Exercise Training with Weight Loss and Either a High- or Low-Glycemic Index Diet Reduces Metabolic Syndrome Severity in Older Adults. *Ann. Nutr. Metab.* 2012, 61, 135–141. [CrossRef]

44. Sattin, R.W.; Williams, L.B.; Dias, J.; Garvin, J.T.; Marion, L.; Joshua, T.V.; Kriska, A.; Kramer, M.K.; Narayan, K.M.V. Community Trial of a Faith-Based Lifestyle Intervention to Prevent Diabetes Among African-Americans. *J. Community Health* 2016, 41, 87–96. [CrossRef]

45. Ard, J.D.; Carson, T.L.; Shikany, J.M.; Li, Y.; Hardy, C.M.; Robinson, J.C.; Williams, A.G.; Baskin, M.L. Weight Loss and Improved Metabolic Outcomes amongst Rural African American Women in the Deep South: Six-Month Outcomes from a Community-Based Randomized Trial. *J. Intern. Med.* 2017, 282, 102–113. [CrossRef]

46. Wang, J.; Cai, C.; Padhye, N.; Orlander, P.; Zane, M. A Behavioral Lifestyle Intervention Enhanced With Multiple-Behavior Self-Monitoring Using Mobile and Connected Tools for Underserved Individuals With Type 2 Diabetes and Comorbid Overweight or Obesity: Pilot Comparative Effectiveness Trial. *JMIR mHealth uHealth* 2018, 6, e92. [CrossRef]

47. Messier, S.P.; Mihalko, S.L.; Legault, C.; Miller, G.D.; Nicklas, B.J.; DeVita, P.; Beavers, D.P.; Hunter, D.J.; Lyles, M.F.; Eckstein, F.; et al. Effects of Intensive Diet and Exercise on Knee Joint Loads, Inflammation, and Clinical Outcomes among Overweight and Obese Adults with Knee Osteoarthritis: The IDEA Randomized Clinical Trial. *JAMA* 2013, 310, 1263–1273. [CrossRef]

48. Villareal, D.T.; Chode, S.; Parimi, N.; Sinacore, D.R.; Hilton, T.; Armamento-Villareal, R.; Napoli, N.; Qualls, C.; Shah, K. Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. *N. Engl. J. Med.* 2011, 364, 1218–1229. [CrossRef] [PubMed]

49. Foster-Schubert, K.E.; Alfano, C.M.; Duggan, C.R.; Xiao, L.; Campbell, K.L.; Kong, A.; Bain, C.E.; Wang, C.Y.; Blackburn, G.L.; Mctiernan, A. Effect of Diet and Exercise, Alone or Combined, on Weight and Body Composition in Overweight-to-Obese Postmenopausal Women. *Obesity* 2012, 20, 1628–1638. [CrossRef]

50. Tomeleri, C.M.; Ribeiro, A.S.; Souza, M.F.; Schiavoni, D.; Schoenfeld, B.J.; Venturini, D.; Barbosa, D.S.; Landucci, K.; Sardinha, L.B.; Cyrino, E.S. Resistance Training Improves Inflammatory Level, Lipid and Glycemic Profiles in Obese Older Women: A Randomized Controlled Trial. *Exp. Gerontol.* 2016, 84, 80–87. [CrossRef] [PubMed]

51. Nicklas, B.J.; Dennis, K.E.; Berman, D.M.; Sorkin, J.; Ryan, A.S.; Goldberg, A.P. Lifestyle Intervention of Hypocaloric Dieting and Walking Reduces Abdominal Obesity and Improves Coronary Heart Disease Risk Factors in Obese, Postmenopausal, African-American and Caucasian Women. *J. Gerontol. A. Biol. Sci. Med. Sci.* 2003, 58, 181–189. [CrossRef]

52. Arad, A.D.; DiMenna, F.J.; Thomas, N.; Tamis-Holland, J.; Weil, R.; Geliebter, A.; Albu, J.B. High-Intensity Interval Training without Weight Loss Improves Exercise but Not Basal or Insulin-Induced Metabolism in Overweight/Obese African American Women. *J. Appl. Physiol.* 2015, 119, 352–362. [CrossRef]
53. Ortmeyer, H.K.; Goldberg, A.P.; Ryan, A.S. Exercise with Weight Loss Improves Adipose Tissue and Skeletal Muscle Markers of Fatty Acid Metabolism in Postmenopausal Women. Obesity (Silver Spring) 2017, 25, 1246–1253. [CrossRef]

54. Wing, R.R.; Anglin, K. Effectiveness of a Behavioral Weight Control Program for Blacks and Whites with NIDDM. Diabetes Care 1996, 19, 409–413. [CrossRef] [PubMed]

55. Fisher, G.; Hyatt, T.C.; Hunter, G.R.; Oster, R.A.; Desmond, R.A.; Gower, B.A. Markers of Inflammation and Fat Distribution Following Weight Loss in African-American and White Women. Obesity 2012, 20, 715–720. [CrossRef]

56. Racette, S.B.; Weiss, E.P.; Obert, K.A.; Kohrt, W.M.; Holloszy, J.O. Modest Lifestyle Intervention and Glucose Tolerance in Obese African Americans. Obes. Res. 2001, 9, 348–355. [CrossRef] [PubMed]

57. Winnick, J.I.; Gaillard, T.; Schuster, D.P. Resistance Training Differentially Affects Weight Loss and Glucose Metabolism of White and African American Patients with Type 2 Diabetes Mellitus. Ethn. Dis. 2008, 18, 152–156. [PubMed]

58. Smith-Ray, R.L.; Fitzgibbon, M.L.; Tussing-Humphreys, L.; Schiffer, L.; Shah, A.; Huber, G.M.; Braunschweig, C.; Campbell, R.T.; Hughes, S.L. Fit and Strong! Plus: Design of a Comparative Effectiveness Evaluation of a Weight Management Program for Older Adults with Osteoarthritis. Contemp. Clin. Trials 2014, 37, 178–188. [CrossRef] [PubMed]

59. Pfieffer, E. A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients. J. Am. Geriatr. Soc. 1975, 23, 433–441. [CrossRef] [PubMed]

60. Ory, M.; Resnick, B.; Jordan, P.J.; Coday, M.; Riebe, D.; Garber, C.E.; Pruitt, L.; Bazzarre, T. Screening, Safety, and Adverse Events in Physical Activity Interventions: Collaborative Experiences from the Behavior Change Consortium. Ann. Behav. Med. 2005, 29, 20–28. [CrossRef]

61. Belza, B. Moving Ahead. Strategies and Tools to Plan, Conduct, and Maintain Effective Community-Based Physical Activity Programs for Older Adults: A Brief Guide; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2007.

62. Centers for Disease Control and Prevention (CDC); National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Questionnaire (or Examination Protocol, or Laboratory Protocol); U.S. Department of Health and Human Services: Hyattsville, MD, USA, 2013.

63. Wallace, T.M.; Levy, J.C.; Matthews, D.R. Use and Abuse of HOMA Modeling. Diabetes Care 2004, 27, 1487–1495. [CrossRef]

64. Hardin, J.W.; Hilbe, J.M. Generalized Estimating Equations: Introduction. In Wiley StatsRef: Statistics Reference Online; Wiley Online Library: Hoboken, NJ, USA, 2014.

65. Carey, D.G.; Jenkins, A.B.; Campbell, L.V.; Freudent, J.; Chisholm, D.J. Abdominal Fat and Insulin Resistance in Normal and Overweight Women: Direct Measurements Reveal a Strong Relationship in Subjects at Both Low and High Risk of NIDDM. Diabetes 1996, 45, 633–638. [CrossRef]

66. Ascaso, J.F.; Pardo, S.; REAL, J.T.; Lorente, R.I.; Friego, A.; Carmena, R. Diagnosing Insulin Resistance by Simple Quantitative Methods in Subjects with Normal Glucose Metabolism. Diabetes Care 2003, 26, 3320–3325. [CrossRef]

67. Hughes, S.L.; Tussing-Humphreys, L.; Schiffer, L.; Smith-Ray, R.; Marquez, D.X.; Demott, A.D.; Berbaum, M.L.; Fitzgibbon, M.L. Fit & Strong! Plus Trial Outcomes for Obese Older Adults with Osteoarthritis. Gerontologist 2020, 60, 558–570.

68. Heaney, M.L.; Golde, D.W. Soluble Receptors in Human Disease. J. Leukoc. Biol. 1998, 64, 135–146. [CrossRef]

69. Mohamed-Ali, V.; Goodrick, S.; Ravesh, A.; Katz, D.R.; Miles, J.M.; Yudkin, J.S.; Klein, S.; Coppel, S.W. Subcutaneous Adipose Tissue Releases Interleukin-6, but Not Tumor Necrosis Factor-Alpha, in Vivo. J. Clin. Endocrinol. Metab. 1997, 82, 4196–4200. [PubMed]

70. Kern, P.A.; Ranganathan, S.; Li, C.; Wood, L.; Ranganathan, G. Adipose Tissue Tumor Necrosis Factor and Interleukin-6 Expression in Human Obesity and Insulin Resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E745–E751. [CrossRef] [PubMed]
71. Tam, C.S.; Xie, W.; Johnson, W.D.; Cefalu, W.T.; Redman, L.M.; Ravussin, E. Defining Insulin Resistance from Hyperinsulinemic-Euglycemic Clamps. *Diabetes Care* **2012**, *35*, 1605–1610. [CrossRef] [PubMed]

72. Fisher, G.; Hyatt, T.C.; Hunter, G.R.; Oster, R.A.; Desmond, R.A.; Gower, B.A. Effect of Diet With and Without Exercise Training on Markers of Inflammation and Fat Distribution in Overweight Women. *Obesity (Silver Spring)* **2011**, *19*, 1131–1136. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).